Intensity Therapeutics, Inc. cash flow to debt ratio of -8.39K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Intensity Therapeutics, Inc.'s free cash flow has increased -39.34% from $-15.22M last year to $-9.23M, signaling increasing performance

Intensity Therapeutics, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

Intensity Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.05 last year to 0.01 today, signaling strengthened financials

Intensity Therapeutics, Inc. has a net cash position, so leverage is healthy.

Intensity Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Intensity Therapeutics, Inc. has insufficient data to evaluate this check.

Intensity Therapeutics, Inc.'s short-term assets of $12.71M exceed its short-term liabilities of $2.15M

Intensity Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Intensity Therapeutics, Inc.'s return on equity of -116.61%, is lower than 15.00%, indicating bad performance

Intensity Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Intensity Therapeutics, Inc. has insufficient public price history to evaluate earnings stability.

Intensity Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Intensity Therapeutics, Inc. has negative free cash flow, indicating cash burn

Intensity Therapeutics, Inc.'s yearly earnings has increased -28.66% since last year from $-16.27M to $-11.61M, signaling increasing performance

Intensity Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -123.35% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Intensity Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Intensity Therapeutics, Inc. has insufficient public price history to evaluate revenue consistency.

Intensity Therapeutics, Inc. has insufficient public price history to evaluate ROE consistency.

Intensity Therapeutics, Inc. has insufficient data to evaluate this check.

Intensity Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Intensity Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Intensity Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Intensity Therapeutics, Inc. has insufficient data to evaluate this check.

Intensity Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Intensity Therapeutics, Inc. has a price-to-book ratio of 12.60x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Intensity Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue